The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC
John Strickler, MD, Duke University, Durham, NC, gives an overview of the Phase III CheckMate 8HW trial (NCT04008030), which assessed nivolumab and ipilimumab or chemotherapy in the first-line setting in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Using checkpoint inhibitors resulted in superior progression-free survival (PFS), but additional research is needed to compare nivolumab and ipilimumab with nivolumab alone to properly personalize treatment in this area. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock and Other Ownership Interests – Triumvira Immunologics, Inc
Consulting or Advisory Role – Abbvie; Amgen; AstraZeneca; Bayer; Beigene; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Natera (Inst); Pfizer; Roche/Genentech; Seagen; Taiho Oncology; Takeda
Research Funding – A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly (Inst); Erasca, Inc (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Lilly (Inst); Roche/Genentech (Inst); Seagen (Inst)
Expert Testimony – Seagen
Travel, Accommodations, Expenses – Seagen
